GLSI
Greenwich LifeSciences, Inc.10.40
+0.09+0.87%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
144.09MP/E (TTM)
-Basic EPS (TTM)
-1.46Dividend Yield
0%Recent Filings
8-K
Annual meeting elects directors
Greenwich LifeSciences held its annual meeting on December 18, 2025, with quorum from 8,944,615 shares. All five director nominees—David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock—won election decisively, each garnering over 7 million 'for' votes despite minor abstentions. Stockholders ratified MaloneBailey LLP as auditors for fiscal 2025 with 8,908,299 votes in favor. Board continuity locked in.
10-Q
Q3 FY2025 results
Greenwich LifeSciences posted a Q3 net loss of $4.2M, up 56% y/y from $2.7M, driven by 54% higher R&D at $3.5M and 49% more G&A at $0.7M—both fueled by options grants and clinical trial ramp-up. Nine-month losses hit $11.4M, 48% above prior year, with YTD R&D doubling to $9.6M on GLSI-100 immunotherapy work; EPS fell to $(0.85) across 13.4M diluted shares, consistent with net loss. Cash dipped to $3.8M after $6.7M operating burn, offset by $6.3M ATM equity raises. No debt, just modest related-party accruals. Stock-based comp dominates expenses. Warrant exercises added $145K. Competition shadows trial outcomes.
10-Q
Q2 FY2025 results
Greenwich LifeSciences posted a Q2 net loss of $4.0M, up 55% y/y from $2.6M, while YTD loss hit $7.3M, 44% above $5.1M last year—purely from ramped R&D ($3.5M, +52% y/y) and G&A ($0.5M, +52% y/y) tied to options grants and clinical trial costs for its breast cancer immunotherapy. No revenue yet, as expected in Phase III. Cash dipped to $3.1M after $4.1M burn on operations, offset by $3.1M from ATM stock sales; equity remains positive at $1.4M. ATM proceeds keep it funded short-term. Losses reconcile across statements. Clinical trial delays pose key risk.
8-K
Auditor dismissed amid weaknesses
Greenwich LifeSciences dismissed RBSM LLP as its auditor effective July 19, 2025, and hired MaloneBailey LLP to audit 2025 financials. RBSM's prior reports were clean, but material weaknesses in internal controls persisted from 2023-2025 filings. No disagreements occurred. Auditor switch flags control issues.
10-Q
Q1 FY2025 results
Greenwich LifeSciences posted a $3.3M net loss for Q1 ended March 31, 2025, up 32% y/y from $2.5M, driven by R&D expenses climbing 19% to $2.6M and G&A doubling to $681K on stock-based compensation of $1.5M. No revenue yet, as Flamingo-01 Phase III advances. Cash burned $1.8M in operations (derived), offset by $492K from ATM stock sales, leaving $2.7M on hand—down from $4.1M at year-end. Stockholders' equity holds at $1.3M. ATM continues post-quarter. Diluted EPS reconciles at $(0.25) on 13.2M shares. Cash runway shrinks fast.
IPO
Employees
Sector
Industry
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
GLTO
Galecto, Inc.
30.00-1.60
GNLX
Genelux Corporation
4.10+0.02
GRI
GRI Bio, Inc.
0.48+0.00
GTBP
GT Biopharma, Inc.
0.72+0.09
IMRX
Immuneering Corporation
5.74-0.04
KZR
Kezar Life Sciences, Inc.
6.30+0.02
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
SLS
SELLAS Life Sciences Group, Inc
2.20+0.16
TLSA
Tiziana Life Sciences Ltd
1.55-0.04